扶正防癌方对晚期非小细胞肺癌患者T淋巴细胞亚群、调节性T淋巴细胞及炎症相关因子水平的影响  

Effect of Fuzheng Fangai Formula on t lymphocyte subsets,peripheral regulatory T Cells and inflammation-related factors in patients with advanced non-small cell lung cancer

作　　者：陈贵敏 韩雨霏 王玉梅 CHEN Guimin;HAN Yufei;WANG Yumei(The Second Ward,Department of Internal Medicine,Linyi Cancer Hospital,Linyi,Shandong 276000;Second Department of General Surgery,Linyi Cancer Hospital,Linyi,Shandong 276000;The Second Ward,Department of Breast,Linyi Cancer Hospital,Linyi,Shandong 276000)

机构地区：[1]山东省临沂市肿瘤医院内科二病区,山东临沂276000 [2]山东省临沂市肿瘤医院普外二科,山东临沂276000 [3]山东省临沂市肿瘤医院乳腺科二病区,山东临沂276000

出　　处：《河北中医》2022年第4期578-581,共4页Hebei Journal of Traditional Chinese Medicine

基　　金：山东省中医药科技发展计划项目(2019—2020年度)(编号:2019-0734)。

摘　　要：目的观察扶正防癌方对非小细胞肺癌(NSCLC)患者T淋巴细胞亚群、调节性T淋巴细胞(Treg)及炎症相关因子的影响。方法将100例NSCLC患者按照随机数字表法分为2组。对照组50例行常规基础治疗,治疗组50例在对照组治疗基础上加扶正防癌方治疗。2组均28 d为1个疗程,共治疗2个疗程。比较2组治疗前后T淋巴细胞亚群(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、Treg及炎症相关因子[C反应蛋白(CRP)、白细胞介素6(IL-6)、IL-10水平]变化,比较2组近期疗效。结果治疗组疾病控制率为40%(20/50),有效率为0,对照组分别为32%(16/50)、0,2组疾病控制率和有效率比较差异均无统计学意义(P>0.05)。治疗后,2组CD4^(+)、CD4^(+)/CD8^(+)水平均较本组治疗前升高(P<0.05),CD8^(+)、Treg水平均较本组治疗前下降(P<0.05),且治疗组CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组(P<0.05),CD8^(+)、Treg水平低于对照组(P<0.05)。治疗后,2组IL-10、CRP、IL-6水平均较本组治疗前显著降低(P<0.05),且治疗组IL-10、IL-6、CRP水平均低于对照组(P<0.05)。结论扶正防癌方治疗NSCLC,可有效降低炎症相关因子水平,同时调节T淋巴细胞亚群及Treg水平。Objective To observe the effect of Fuzheng Fangai Formula on immune function,peripheral regulatory T cells(Tregs)and inflammatory cytokines in patients with non-small cell lung cancer(NSCLC).Methods Totally 100 NSCLC patients were randomly divided into the control group and the treatment group,with 50 cases in each;in addition to conventional basic treatment,and treatment group received Fuzheng Fangai Formula.The treatment continued for 2 course(1 course for 28 days),the aim was to compare t lymphocyte subset(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)and Treg),C-reactive protein(CRP),interleukin-6(IL-6),IL-10;the short-term effect was assessed.Results The control rate of disease in the treatment group and the control group was 40%(20/50)and 32%(16/50),respectively;the effective rate in both groups was 0;the difference of two groups being not significant(P>0.05).After treatment,CD4^(+),CD4^(+)/CD8^(+)in groups were increased(P<0.05),the treatment group was more common(P<0.05);CD8^(+)and Treg in groups were decreased(P<0.05),the treatment group was more prevalent(P<0.05);IL-10,CRP,IL-6 in groups were notably decreased(P<0.05),which were lower in the treatment group than in the control group(P<0.05).Conclusion For NSCLC patients,Fuzheng Fangai Formula can effectively reduce the levels of inflammatory cytokines,regulate immune function and Treg levels.

关 键 词：癌 非小细胞肺 中药疗法 T淋巴细胞 调节性 免疫 炎症 

分 类 号：R734.205.31[医药卫生—肿瘤]